findmyKOL
Clinical trialNCT00007202CompletedPhase 2Interventional

Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment55HIV Infections
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the safety and effectiveness of stavudine (d4T), didanosine (ddI), and BMS-232632 when given early in the course of HIV infection. Acute HIV infection may develop in patients that are exposed to the HIV virus. Following infection, the viral load (level of HIV in the blood) rises rapidly over the next few days to weeks. It is not known which is the best treatment in patients with very early HIV infection. Researchers believe these patients may respond well to strong early treatment. A combination consisting of enteric-coated didanosine (ddI-EC), stavudine (d4T), and the HIV-1 protease inhibitor, BMS-232632, will be tested.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Brazil
  • Centro de Referencia Estadual de Aids Aiedrp

    Salvador, Estado de Bahia, Brazil

United States
  • Univ. of Colorado Health Sciences Ctr. Aiedrp

    Denver, Colorado, United States

  • Aids Research Consortium of Atlanta, Inc. (arca) Aiedrp Crs

    Atlanta, Georgia, United States

  • Feinberg School of Medicine, Hiv/actu Aiedrp Crs

    Chicago, Illinois, United States

  • Rush Univ. Med. Ctr., Dept. of Infectious Disease Aiedrp Crs

    Chicago, Illinois, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AtazanavirDidanosineStavudine
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
—
Primary completion
—
Completion
31 Oct 2006
Last update posted
1 Nov 2021
Registered enrollment
55
Registry id
NCT00007202
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.